Novo Nordisk announces expansion of Hillerød API manufacturing facility
Novo Nordisk will invest 15.9 billion Danish kroner into the expansion of their existing API manufacturing facility.
Novo Nordisk have announced on June 12, 2023 that they are to invest DKK 15.9 billion kr. for the expansion of their API manufacturing facility in Denmark for products that treat serious chronic diseases, such as diabetes.
The current production facility, located in Hillerød, Denmark, will benefit from the investment with increased production capacity and enable the Danish pharmaceutical company to meet market demands in the future regarding drug products for chronic diseases. The facility will particularly develop Novo Nordisk’s ability to develop a clinical late-phase product portfolio in the future.
An additional 65,000 m2 will be added to design a multi-product facility and house state-of-the-art technology to ensure flexibility in accommodating new processes. The new facility will be geared towards delivering high-quality drug products compliant with environmental sustainability regulations through the use of compact and optimal process flow that reduce the consumption of water and energy. Construction has already begun, with the facility to start producing APIs by 2029, creating 340 new jobs within the region.
Henrik Wulff, Executive VP of Product Supply, Quality & IT at Novo Nordisk, highlighted the importance of the investment and the healthcare opportunities that can be provided with the right infrastructure: “This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” he commented. “The investment announced today confirms Hillerød and Denmark as cornerstones in our global footprint, and I would like to take this opportunity to thank the Danish Government and Parliament for their continued focus on ensuring good and stable infrastructure and supplies – allowing us to continue to expand our production capacity to the benefit of patients living with serious chronic diseases.”
Source: Novo Nordisk invests DKK 15.9 bn in expansion of manufacturing facilities in Hillerød, Denmark [Accessed June 12, 2023] https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166116
Related News
-
News Pharma CEOs write open letter calling suppliers to commit to sustainability
Several big pharma companies have added their names to a letter challenging suppliers in the healthcare industry to pledge to sustainability targets. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News Ardena forms partnership with RiboPro to improve mRNA-based therapies
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. -
News Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News Women in Pharma: Gearing up for systemic change
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Delivering on mRNA-based therapeutics: innovations in applications and packaging
Since the onset of the COVID-19 pandemic, the innovative potential of mRNA vaccines and therapeutics has raised questions regarding their manufacturing, packaging, and storage/transportation. Learn about how the pharmaceutical supply chain is meet... -
News Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance